Women’s healthcare company TherapeuticsMD announced it has received a notice of allowance from the U.S. Patent and Trademark Office regarding its U.S. patent application 13/684,002, “Natural Combination Hormone Replacement Formulations and Therapies.” The patent application covers TherapeuticsMD’s technology TX 12-001-HR, an oral bioidentical 17-estradiol and progesterone combination drug candidate.

The receipt of this patent allowance is a key step for TherapeuticsMD toward solidifying its IP protection for this important technology, particularly in relation to lead product candidate TX 12-001-HR. Previously, it has been extremely difficult to combine the bioidentical hormones 17-estradiol and progesterone and achieve consistent bioavailability. Based on clinical data that was presented earlier this year, TherapeuticsMD believes TX 12-001-HR has overcome past obstacles and that this novel combination of 17-estradiol and progesterone may successfully achieve equivalent efficiency with improved bioavailability, as compared with current hormone therapies. The company eagerly awaits the outcome of its ongoing REPLENISH Trial.

A women’s healthcare company, TherapeuticsMD is focused on the development and commercialization of products targeted exclusively at women. The company is in the process of developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bioidentical hormones through various dosage forms and administration routes. TherapeuticsMD also manufactures and distributes branded and generic prescription prenatal vitamins and over-the-counter vitamins and cosmetics under its vitaMedMD and BocaGreenMD brands.

For more information, visit www.therapeuticsmd.com

Let us hear your thoughts below: